Health

Coreline Soft supplies cardiovascular imaging software AVIEW CAC to Japanese telemedicine firm Doctor Net.

Samsung Biologics achieves 87.88% participation in Polypeptide Group's tender offer, exceeding the minimum acceptance condition of 66.7%.

Study shows reducing radiation therapy sessions from 33 to 26 maintains similar cancer suppression in prostate cancer patients.

Lunit has signed a strategic partnership with Discovery Life Sciences to combine its AI-powered pathology platform with the U.S. company’s biospecimen and analytical capabilities, supporting biomarker analysis and drug development for global pharmaceutical companies.

Incheon Naeun Hospital introduces a backup and recovery solution for medical data, marking the first implementation in South Korea.

Ildong Pharmaceutical seeks to expand drug exports and contract manufacturing at a global pharmaceutical exhibition in Milan.

Park Young-min emphasized the importance of global partnerships to translate promising research results into actual drug development.

Dongkook Pharmaceutical plans to change its name to DK Centellian, expanding into healthcare and beauty for global market growth.

Daewoong Bio expands its diagnostic business to detect Alzheimer's signs through blood tests, simplifying detection compared to existing methods.

HK inno.N’s U.S. partner Sebela Pharmaceuticals will present Phase 3 results for K-CAB in non-erosive gastroesophageal reflux disease, with the trial showing significant improvements in heartburn-free days at both tested doses.

HLB and its partners have resubmitted an application for rivoceranib and camrelizumab as a first-line liver cancer treatment, about three months after receiving an FDA Complete Response Letter, citing Phase 3 results showing a median overall survival of 23.8 months.

Korean spine implant makers are shifting their U.S. focus from securing FDA clearance to expanding hospital registrations, clinical use and repeat adoption by surgeons, with Medyssey, L&K Biomed and CG MedTech advancing their market presence.

HLB is accelerating plans to resubmit its liver cancer drug rivoceranib in the U.S. after securing FDA approval for cholangiocarcinoma treatment Riptivo and receiving favorable inspection classifications for its manufacturing facilities.

Lotte Biologics is stepping up efforts to win Japanese pharmaceutical and biotech clients by highlighting the manufacturing capabilities and quality management of its Syracuse facility, following a contract with Alvotech.